Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies

References

• Vallat J-M. Peripheral nervous system neuroimmunology seen by a neuro-pathologist. Rev Neurol (Paris). 2014;170:564–569.
   PubMed Web of Science ®Google Scholar
• Notermans NC, Wokke JH, Lokhorst HM, et al. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain. 1994;117:1385–1393.
   PubMed Web of Science ®Google Scholar
• Alkhawajah NM, Dunnigan SK, Bril V. Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. J Neurol. 2014;261:1485–1491.
   PubMed Web of Science ®Google Scholar
• Pruppers MH, Merkies IS, Notermans NC. Recent advances in outcome measures in IgM-anti-MAG+ neuropathies. Curr Opin Neurol. 2015;28:486–493.
   PubMed Web of Science ®Google Scholar
• Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12:102–110.
   PubMed Web of Science ®Google Scholar
• Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand. 1966;179:235–247.
   PubMedGoogle Scholar
• Saleun JP, Vicariot M, Deroff P, et al. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982;35:63–68.
   PubMed Web of Science ®Google Scholar
• Crawford J, Cohen HJ. An approach to monoclonal gammopathies in the elderly. Geriatrics. 1982;37:97–100, 5–6, 11–12.
   PubMedGoogle Scholar
• Kyle RA. Monoclonal gammopathy of undetermined significance. Blood Rev. 1994;8:135–141.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85:383–390.
   PubMed Web of Science ®Google Scholar
• Vrethem M, Cruz M, Wen-Xin H, et al. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci. 1993;114:193–199.
   PubMed Web of Science ®Google Scholar
• Kelly JJ Jr., Kyle RA, Miles JM, et al. The spectrum of peripheral neuropathy in myeloma. Neurology. 1981;31:24–31.
   PubMed Web of Science ®Google Scholar
• Mathis S, Vallat JM, Ingrand P, et al. Causes of neuropathy in the elderly: a retrospective study with 785 patients. Eur Ger Med. 2015;6:114–118.
   Web of Science ®Google Scholar
• Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37:1506–1514.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Francomano E, Daverio R, et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol. 1989;26:543–550.
   PubMed Web of Science ®Google Scholar
• Dubas F, Pouplard-Barthelaix A, Delestre F, et al. Polyneuropathies avec gammapathie monoclonale IgM. 12 cas. Rev Neurol (Paris). 1987;143:670–683.
   PubMed Web of Science ®Google Scholar
• Vital A, Vital C, Julien J, et al. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol. 1989;79:160–167.
   PubMed Web of Science ®Google Scholar
• Kelly JJ Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve. 1985;8:138–150.
   PubMed Web of Science ®Google Scholar
• Latov N, Braun PE, Gross RB, et al. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci U S A. 1981;78:7139–7142.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol. 2010;12:71–83.
   PubMed Web of Science ®Google Scholar
• Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615–620.
   PubMed Web of Science ®Google Scholar
• Magy L, Kaboré R, Mathis S, et al. Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res. 2015;2015:450391.
   PubMed Web of Science ®Google Scholar
• Bain PG, Britton TC, Jenkins IH, et al. Tremor associated with benign IgM paraproteinaemic neuropathy. Brain. 1996;119:789–799.
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst. 2010;15:185–195.
   PubMed Web of Science ®Google Scholar
• Eurelings M, Ang CW, Notermans NC, et al. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology. 2001;57:1909–1912.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Hays AP, Latov N, et al. Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology. 1984;34:1336–1342.
   PubMed Web of Science ®Google Scholar
• Braun PE, Frail DE, Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982;39:1261–1265.
   PubMed Web of Science ®Google Scholar
• Chou KH, Ilyas AA, Evans JE, et al. Structure of a glycolipid reacting with monoclonal IgM in neuropathy and with HNK-1. Biochem Biophys Res Commun. 1985;128:383–388.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Whitaker JN, et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol. 1985;17:243–254.
   PubMed Web of Science ®Google Scholar
• Smith IS, Kahn SN, Lacey BW, et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain. 1983;106:169–195.
   PubMed Web of Science ®Google Scholar
• Dancea S, Dellagi K, Renaud F, et al. Effect of passive transfer of human anti-myelin-associated glycoprotein IgM in marmoset. Autoimmunity. 1989;3:29–37.
   PubMed Web of Science ®Google Scholar
• Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993;33:502–506.
   PubMed Web of Science ®Google Scholar
• Ritz MF, Erne B, Ferracin F, et al. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve. 1999;22:1030–1037.
   PubMed Web of Science ®Google Scholar
• Vital A, Latinville D, Aupy M, et al. Inflammatory demyelinating lesions in two patients with IgM monoclonal gammopathy and polyneuropathy. Neuropathol Appl Neurobiol. 1991;17:415–420.
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Gu Y, Dalakas MC, et al. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. 2008;193:87–93.
   PubMed Web of Science ®Google Scholar
• Li C, Tropak MB, Gerlai R, et al. Myelination in the absence of myelin-associated glycoprotein. Nature. 1994;369:747–750.
   PubMed Web of Science ®Google Scholar
• Montag D, Giese KP, Bartsch U, et al. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron. 1994;13:229–246.
   PubMed Web of Science ®Google Scholar
• Fruttiger M, Montag D, Schachner M, et al. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci. 1995;7:511–515.
   PubMed Web of Science ®Google Scholar
• Kinter J, Lazzati T, Schmid D, et al. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease. Neurobiol Dis. 2013;49:221–231.
   PubMed Web of Science ®Google Scholar
• Erb M, Flueck B, Kern F, et al. Unraveling the differential expression of the two isoforms of myelin-associated glycoprotein in a mouse expressing GFP-tagged S-MAG specifically regulated and targeted into the different myelin compartments. Mol Cell Neurosci. 2006;31:613–627.
   PubMed Web of Science ®Google Scholar
• Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19:458–463.
   PubMed Web of Science ®Google Scholar
• Weiss MD, Dalakas MC, Lauter CJ, et al. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol. 1999;95:174–184.
   PubMed Web of Science ®Google Scholar
• Kawagashira Y, Koike H, Ohyama K, et al. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody. J Neurol Sci. 2015;348:67–73.
   PubMed Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Weinberg DH, et al. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve. 2001;24:778–786.
   PubMed Web of Science ®Google Scholar
• Cook D, Dalakas M, Galdi A, et al. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990;40:212–214.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40:792–795.
   PubMed Web of Science ®Google Scholar
• Ellie E, Vital A, Steck A, et al. Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol. 1996;243:34–43.
   PubMed Web of Science ®Google Scholar
• Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249:1370–1377.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2012;5:CD002827.
   PubMed Web of Science ®Google Scholar
• Kaveri SV, Lecerf M, Saha C, et al. Intravenous immunoglobulin and immune response. Clin Exp Immunol. 2014;178(Suppl 1):94–96.
   PubMed Web of Science ®Google Scholar
• Sherman WH, Olarte MR, McKiernan G, et al. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry. 1984;47:813–819.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325:1482–1486.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Chevret S, Léger JM, et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1995;59:243–247.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123:710–717.
   PubMed Web of Science ®Google Scholar
• Shaz BH, Schwartz J, Winters JL. How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures? Transfusion. 2014;54:17–25.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28:145–284.
   PubMed Web of Science ®Google Scholar
• Kiprov DD, Golden P, Rohe R, et al. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apher. 2001;16:130–133.
   PubMed Web of Science ®Google Scholar
• Mariette X, Chastang C, Clavelou P, et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997;63:28–34.
   PubMed Web of Science ®Google Scholar
• Mariette X, Brouet JC, Chevret S, et al. A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry. 2000;69:279–280.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Engel WK. Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Ann Neurol. 1981;10:45–52.
   PubMed Web of Science ®Google Scholar
• Notermans NC, Lokhorst HM, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology. 1996;47:1227–1233.
   PubMed Web of Science ®Google Scholar
• Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology. 1995;45:1577–1580.
   PubMed Web of Science ®Google Scholar
• Niermeijer JM, Eurelings M, Van Der Linden MW, et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology. 2007;69:50–59.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Littlewood T, Donaghy M. Cladribine in the treatment of IgM paraproteinemic polyneuropathy. Neurology. 2002;59:1290–1291.
   PubMed Web of Science ®Google Scholar
• Rossi D, Franceschetti S, Cerri M, et al. Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribrine treatment. Leuk Res. 2007;31:873–876.
   PubMed Web of Science ®Google Scholar
• Andrès E, Vinzio S, Maloisel F, et al. Neuropathies périphériques auto-immunes à anticorps anti-MAG et hémopathies. A propos de 5 observations. Ann Med Interne (Paris). 2001;152:147–151.
   PubMedGoogle Scholar
• Sherman WH, Latov N, Lange D, et al. Fludarabine for IgM antibody-mediated neuropathies. 119th Annual Meeting of the American Neurological Association; 1994Oct 9–12; San Fransico, CA; p. 326.
   Google Scholar
• Niermeijer JM, Eurelings M, Lokhorst H, et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology. 2006;67:2076–2079.
   PubMed Web of Science ®Google Scholar
• Wilson HC, Lunn MP, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66:575–580.
   PubMed Web of Science ®Google Scholar
• Rudnicki SA, Harik SI, Dhodapkar M, et al. Nervous system dysfunction in Waldenstrom’s macroglobulinemia: response to treatment. Neurology. 1998;51:1210–1213.
   PubMed Web of Science ®Google Scholar
• Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701–1704.
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–489.
   PubMed Web of Science ®Google Scholar
• Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve. 2003;27:611–615.
   PubMed Web of Science ®Google Scholar
• Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology. 2006;66:742–744.
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007;12:102–107.
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuropathy. Neurology. 2008;71:1742–1744.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–293.
   PubMed Web of Science ®Google Scholar
• Léger J-M, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217–2225.
   PubMed Web of Science ®Google Scholar
• Iancu Ferfoglia R, Guimarães-Costa R, Viala K, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016;21:10–14.
   PubMed Web of Science ®Google Scholar
• Souayah N, Noopur R, Tick-Chong PS. Beneficial effects of rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports. Immunopharmacol Immunotoxicol. 2013;35:622–624.
   PubMed Web of Science ®Google Scholar
• Hospital M-A, Viala K, Dragomir S, et al. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica. 2013;98:e155–e157.
   PubMed Web of Science ®Google Scholar
• Glavey SV, Leung N. Monoclonal gammopathy: the good, the bad and the ugly. Blood Rev. 2015;30:223–231.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma. 2005;6:102–114.
   PubMedGoogle Scholar
• Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85:945–948.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–1369.
   PubMed Web of Science ®Google Scholar
• Koya J, Iwata A, Nakamura F, et al. Fludarabine may overcome resistance to rituximab in IgM-related neuropathy. J Neurol Sci. 2012;315:150–152.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014;59(Suppl 5):360–364.
   PubMed Web of Science ®Google Scholar
• Garrote H, De La Fuente A, Oña R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015;4:8.
   PubMedGoogle Scholar
• Hamada Y, Hirano M, Kuwahara M, et al. Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: possible clinical relevance. Neurosci Res. 2015;91:63–68.
   PubMed Web of Science ®Google Scholar
• Julien J, Vital C, Vallat JM, et al. IgM demyelinative neuropathy with amyloidosis and biclonal gammopathy. Ann Neurol. 1984;15:395–399.
   PubMed Web of Science ®Google Scholar
• Garces-Sanchez M, Dyck PJ, Kyle RA, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37:490–495.
   PubMed Web of Science ®Google Scholar
• Duchesne M, Mathis S, Corcia P, et al. Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series. Medicine (Baltimore). 2015;94:e394.
   PubMed Web of Science ®Google Scholar
• Pedersen SF, Pullman SL, Latov N, et al. Physiological tremor analysis of patients with anti-myelin-associated glycoprotein associated neuropathy and tremor. Muscle Nerve. 1997;20:38–44.
   PubMed Web of Science ®Google Scholar
• Saverino A, Solaro C, Capello E, et al. Tremor associated with benign IgM paraproteinaemic neuropathy successfully treated with gabapentin. Mov Disord. 2001;16:967–968.
   PubMed Web of Science ®Google Scholar
• Latino P, Pellicano C, Pontieri FE, et al. Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor. Neurol Sci. 2015;36:333–334.
   PubMed Web of Science ®Google Scholar
• Bayreuther C, Delmont E, Borg M, et al. Deep brain stimulation of the ventral intermediate thalamic nucleus for severe tremor in anti-MAG neuropathy. Mov Disord. 2009;24:2157–2158.
   PubMed Web of Science ®Google Scholar
• Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13:292–307.
   PubMedGoogle Scholar
• Cruccu G. Treatment of painful neuropathy. Curr Opin Neurol. 2007;20:531–535.
   PubMed Web of Science ®Google Scholar